Examines the impact of increased transparency on the legal, medical, and business structures of the American health care system.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Introduction Carmel Shachar, I. Glenn Cohen, Holly Fernandez Lynch and Barbara J. Evans; Part I. Transparency in Health and Health Care: Thematic Issues: Introduction Abigail R. Moncrieff; 1. Smashing into windows: 'the limits of consumer sovereignty in health care' Barry R. Furrow; 2. The interplay of privacy and transparency in health care: the HIPAA privacy rule as a case study Barbara J. Evans; 3. Transparency tradeoffs: priority-setting, scarcity, and health fairness Govind Persad; 4. Slightly hazy: transparency and the costs of too much information Oliver J. Kim; Part II. Transparency and Informed Consent: Introduction Luke Gelinas; 5. Transparency versus informed consent: the patient/consumer paradigms Craig J. Konnoth; 6. Transparency and financial conflicts: the uncertain case for sunshine Richard S. Saver; 7. Making religion transparent: the substance, process, and efficacy of disclosing religious restrictions on care Elizabeth Sepper; Part III. Transparency and Economics: Health Care Costs and Billing: Introduction Kristin M. Madison; 8. Transparency on prescription drug research expenditures: a lever for restraining pricing? Ameet Sarpatwari, Jerry Avorn and Aaron S. Kesselheim; 9. Is pharmaceutical price transparency an effective means to reduce high prices and wide variations? Marc A. Rodwin; 10. Price transparency: a contracts solution Wendy Netter Epstein; 11. Solving surprise medical bills Mark A. Hall; Part IV. Transparency and Innovation: Introduction Holly Fernandez Lynch; 12. Increasing the transparency of FDA review to enhance the innovation process Rachel E. Sachs and Thomas J. Hwang; 13. Transparency and clinical trial data sharing: legal and policy issues Barbara E. Bierer, Mark Barnes and Rebecca Li; 14. The European Medicines Agency's approach to transparency Stefano Marino and Spyridon Drosos; Part V. Transparency and Outcomes: Promoting Health and Safety: Introduction Gregory Curfman; 15. The role of transparency in promoting healthy behaviors: pros, cons, and perils of information sharing to foster personal responsibility in health care Anthony W. Orlando and Arnold J. Rosoff; 16. The role of transparency in patient safety improvement Michelle M. Mello, David M. Studdert, Brahmajee K. Nallamothu and Allen Kachalia; 17. Personal health records as a tool for transparency in health care Sharona Hoffman; 18. Nontransparency in electronic health record systems Jim Hawkins, Barbara J. Evans and Harlan M. Krumholz; 19. Transparency challenges in reproductive health care Dov Fox; Part VI. Challenges in Promoting and Measuring Transparency in Health Care: Introduction I. Glenn Cohen; 20. ERISA as a barrier for state health care transparency efforts Erin C. Fuse Brown and Jaime S. King; 21. Transparency and data sharing in clinical research and Big Pharma Jennifer E. Miller; 22. Promoting IRB transparency: about what, to whom, why, and how? Holly Fernandez Lynch; 23. Using disclosure to regulate PBMs: the dark side of transparency David A. Hyman and William E. Kovacic.
Introduction Carmel Shachar, I. Glenn Cohen, Holly Fernandez Lynch and Barbara J. Evans; Part I. Transparency in Health and Health Care: Thematic Issues: Introduction Abigail R. Moncrieff; 1. Smashing into windows: 'the limits of consumer sovereignty in health care' Barry R. Furrow; 2. The interplay of privacy and transparency in health care: the HIPAA privacy rule as a case study Barbara J. Evans; 3. Transparency tradeoffs: priority-setting, scarcity, and health fairness Govind Persad; 4. Slightly hazy: transparency and the costs of too much information Oliver J. Kim; Part II. Transparency and Informed Consent: Introduction Luke Gelinas; 5. Transparency versus informed consent: the patient/consumer paradigms Craig J. Konnoth; 6. Transparency and financial conflicts: the uncertain case for sunshine Richard S. Saver; 7. Making religion transparent: the substance, process, and efficacy of disclosing religious restrictions on care Elizabeth Sepper; Part III. Transparency and Economics: Health Care Costs and Billing: Introduction Kristin M. Madison; 8. Transparency on prescription drug research expenditures: a lever for restraining pricing? Ameet Sarpatwari, Jerry Avorn and Aaron S. Kesselheim; 9. Is pharmaceutical price transparency an effective means to reduce high prices and wide variations? Marc A. Rodwin; 10. Price transparency: a contracts solution Wendy Netter Epstein; 11. Solving surprise medical bills Mark A. Hall; Part IV. Transparency and Innovation: Introduction Holly Fernandez Lynch; 12. Increasing the transparency of FDA review to enhance the innovation process Rachel E. Sachs and Thomas J. Hwang; 13. Transparency and clinical trial data sharing: legal and policy issues Barbara E. Bierer, Mark Barnes and Rebecca Li; 14. The European Medicines Agency's approach to transparency Stefano Marino and Spyridon Drosos; Part V. Transparency and Outcomes: Promoting Health and Safety: Introduction Gregory Curfman; 15. The role of transparency in promoting healthy behaviors: pros, cons, and perils of information sharing to foster personal responsibility in health care Anthony W. Orlando and Arnold J. Rosoff; 16. The role of transparency in patient safety improvement Michelle M. Mello, David M. Studdert, Brahmajee K. Nallamothu and Allen Kachalia; 17. Personal health records as a tool for transparency in health care Sharona Hoffman; 18. Nontransparency in electronic health record systems Jim Hawkins, Barbara J. Evans and Harlan M. Krumholz; 19. Transparency challenges in reproductive health care Dov Fox; Part VI. Challenges in Promoting and Measuring Transparency in Health Care: Introduction I. Glenn Cohen; 20. ERISA as a barrier for state health care transparency efforts Erin C. Fuse Brown and Jaime S. King; 21. Transparency and data sharing in clinical research and Big Pharma Jennifer E. Miller; 22. Promoting IRB transparency: about what, to whom, why, and how? Holly Fernandez Lynch; 23. Using disclosure to regulate PBMs: the dark side of transparency David A. Hyman and William E. Kovacic.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
